BriaCell Therapeutics Corp (NASDAQ:BCTX)’s traded shares stood at 0.56 million during the last session, with the company’s beta value hitting 1.63. At the close of trading, the stock’s price was $0.38, to imply a decrease of -1.82% or $0.0 in intraday trading. The BCTX share’s 52-week high remains $4.61, putting it -1113.16% down since that peak but still an impressive 2.63% since price per share fell to its 52-week low of $0.37. The company has a valuation of $16.71M, with an average of 1.18 million shares in intraday trading volume over the past 10 days and average of 1.46 million shares over the past 3 months.

BriaCell Therapeutics Corp (NASDAQ:BCTX) trade information

After registering a -1.82% downside in the last session, BriaCell Therapeutics Corp (BCTX) has traded red over the past five days. The 5-day price performance for the stock is -6.16%, and -37.84% over 30 days. With these gigs, the year-to-date price performance is -33.10%. Short interest in BriaCell Therapeutics Corp (NASDAQ:BCTX) saw shorts transact 0.69 million shares and set a 0.77 days time to cover.

BriaCell Therapeutics Corp (BCTX) estimates and forecasts

Looking at statistics comparing BriaCell Therapeutics Corp share performance against respective industry, we note that the company has underperformed competitors. BriaCell Therapeutics Corp (BCTX) shares are -50.26% down over the last 6 months, with its year-to-date growth rate lower than industry average at -248.28% against 16.60%.

BCTX Dividends

BriaCell Therapeutics Corp has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Going by data provided on Nov 30, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 7.23 shares. This is just over 0.02% of the total shares, with a market valuation of $2732.0